UroStream

Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.

A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.

The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, in collaboration with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Centered around the theme “Global Wisdom, Chinese Practice, Precision Breakthroughs,” the event brought together leading experts to discuss cutting-edge progress and clinical insights in prostate cancer care. In an exclusive interview with Oncology Frontier – Urology Frontier, Professor Xiaojian Qin of Fudan University Shanghai Cancer Center shared his views on how the guiding philosophy in prostate cancer treatment is evolving.

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, alongside the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer…

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress, held from June 27–28 in Shanghai, was organized in conjunction with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC),…

On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.

As the tides of the Pujiang River surge forward, so too does China's momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai from June 27–28. The event gathered leading experts from China and abroad to exchange the latest advances and clinical practices in prostate cancer. In an exclusive interview with Oncology Frontier – Urology Frontier, Congress Chair and Professor Dingwei Ye of Fudan University Shanghai Cancer Center shared his perspectives on the current status and future of prostate cancer care in China, along with recent innovations in surgical treatment.

The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.

The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology (CACA-GO) Prostate Cancer Conference, and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Themed “Global Wisdom · Chinese Practice · Precise Breakthroughs,” the event brought together domestic and international experts to exchange the latest advances and practical experience in prostate cancer.

The 2025 Pujiang Prostate Cancer Academic Conference—held from June 27 to 28 in Shanghai—was jointly hosted by the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the China Prostate Cancer Consortium (CPCC). With the theme "Global Wisdom, Chinese Practice, and Precision Breakthroughs," the conference brought together leading experts from China and abroad to discuss the latest advances and best practices in prostate cancer care. At the meeting, Professor Qiang Wei from West China Hospital, Sichuan University, delivered an insightful presentation on treatment escalation and de-escalation in metastatic hormone-sensitive prostate cancer (mHSPC) and shared key clinical perspectives in an interview with Oncology Frontier – UroStream.